Am J Perinatol 2024; 41(09): 1178-1184
DOI: 10.1055/a-1799-5714
Original Article

Risk Factors for Measles Nonimmunity in Rubella-Immune Pregnant Patients

1   Department of Obstetrics and Gynecology, University of California, Los Angeles (UCLA), Los Angeles, California
,
Kerry Holliman
1   Department of Obstetrics and Gynecology, University of California, Los Angeles (UCLA), Los Angeles, California
,
Masaru Negi
1   Department of Obstetrics and Gynecology, University of California, Los Angeles (UCLA), Los Angeles, California
,
Hai-Lang Duong
1   Department of Obstetrics and Gynecology, University of California, Los Angeles (UCLA), Los Angeles, California
,
Megha D. Tandel
2   Department of Urology, University of California, Los Angeles (UCLA), Los Angeles, California
,
Lorna Kwan
2   Department of Urology, University of California, Los Angeles (UCLA), Los Angeles, California
,
1   Department of Obstetrics and Gynecology, University of California, Los Angeles (UCLA), Los Angeles, California
,
Neil S. Silverman
1   Department of Obstetrics and Gynecology, University of California, Los Angeles (UCLA), Los Angeles, California
,
Rashmi R. Rao
1   Department of Obstetrics and Gynecology, University of California, Los Angeles (UCLA), Los Angeles, California
,
Christina S. Han
1   Department of Obstetrics and Gynecology, University of California, Los Angeles (UCLA), Los Angeles, California
› Institutsangaben
Zoom Image

Abstract

Objective Measles immunity testing, unlike that for rubella, is not currently part of prenatal screening even though immunity to both is conferred by the measles–mumps–rubella (MMR) vaccine. Although endemic transmission of measles was declared eliminated in the United States in 2001, outbreaks have continued to occur. Given the risks associated with measles infection during pregnancy, we sought to identify risk factors for measles nonimmunity (MNI) in rubella-immune (RI) pregnant individuals.

Methods We performed a retrospective observational cross-sectional study of patients receiving prenatal care and delivering at two university hospitals and a county hospital in Southern California from April 1, 2019 to February 1, 2021. Inclusion criteria were pregnant individuals ≥18 years old who had serological testing for rubella and measles during pregnancy. Demographic data were extracted from electronic medical records, including results of serological testing and chronic medical conditions. All subjects were rubella immune, and we compared measles-immune (MI) with MNI groups.

Results In total, 1,813 RI individuals were identified, with 1,467 (81%) MI and 346 (19%) MNI individuals. Variables associated with an increased risk of MNI included having public health insurance (adjusted relative risk [aRR]: 1.56; 95% confidence interval [CI]: 1.24, 1.97) and Hispanic ethnicity (aRR: 1.37; 95% CI: 1.06, 1.78). Black race was associated with a decreased risk of MNI (aRR: 0.52; 95% CI: 0.29, 0.91). Birth year before 1989 demonstrated a trend toward increased risk of MNI, but this did not reach statistical significance (aRR 1.23; 95% CI: 1.00, 1.52). No differences were seen between the two groups for medical comorbidities.

Conclusion Our study is the first to demonstrate risk factors for measles MNI in patients with documented rubella immunity. In the absence of universal measles serological screening recommendations, the risk factors identified could help guide clinicians in selective screening for those at risk of needing postpartum MMR vaccination.

Key Points

  • The rate of measles nonimmunity is higher than previously reported.

  • Hispanic ethnicity and use of public insurance are risk factors for measles nonimmunity.

  • The current recommendation for history-based screening for measles immunity is likely insufficient.

Note

This study was presented via oral presentation at the Infectious Disease Society of Obstetrics and Gynecology 2021 Annual Conference in July 2021.




Publikationsverlauf

Eingereicht: 25. September 2021

Angenommen: 11. März 2022

Accepted Manuscript online:
15. März 2022

Artikel online veröffentlicht:
31. Mai 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

Crossref Cited-by logo
Article Citations